128 related articles for article (PubMed ID: 17022815)
1. Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure.
Hessel FP
Cost Eff Resour Alloc; 2006 Oct; 4():16. PubMed ID: 17022815
[TBL] [Abstract][Full Text] [Related]
2. Extracorporal hemodialysis with acute or decompensated chronical hepatic failure.
Hessel F; Grabein K; Schnell-Inderst P; Siebert U; Caspary W; Wasem J
GMS Health Technol Assess; 2006 Apr; 2():Doc08. PubMed ID: 21289959
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of the artificial liver support system MARS in patients with acute-on-chronic liver failure.
Hessel FP; Bramlage P; Wasem J; Mitzner SR
Eur J Gastroenterol Hepatol; 2010 Feb; 22(2):213-20. PubMed ID: 19773666
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation and 1-year survival analysis of MARS in patients with alcoholic liver disease.
Hessel FP; Mitzner SR; Rief J; Guellstorff B; Steiner S; Wasem J
Liver Int; 2003; 23 Suppl 3():66-72. PubMed ID: 12950964
[TBL] [Abstract][Full Text] [Related]
5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of MARS--preliminary results on survival and quality of life.
Hessel FP; Mitzner SR; Rief J; Gress S; Guellstorff B; Wasem J
Liver; 2002; 22 Suppl 2():26-9. PubMed ID: 12220299
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy.
Hessel FP; Wegner C; Müller J; Glaveris C; Wasem J
Eur J Health Econ; 2004 Feb; 5(1):58-63. PubMed ID: 15452766
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program.
Bourbeau J; Granados D; Roze S; Durand-Zaleski I; Casan P; Köhler D; Tognella S; Viejo JL; Dal Negro RW; Kessler R
Int J Chron Obstruct Pulmon Dis; 2019; 14():645-657. PubMed ID: 30936689
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure.
Kantola T; Mäklin S; Koivusalo AM; Räsänen P; Rissanen A; Roine R; Sintonen H; Höckerstedt K; Isoniemi H
World J Gastroenterol; 2010 May; 16(18):2227-34. PubMed ID: 20458759
[TBL] [Abstract][Full Text] [Related]
10. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of freeze-only or fresh embryo transfer in IVF of non-PCOS women.
Le KD; Vuong LN; Ho TM; Dang VQ; Pham TD; Pham CT; Norman RJ; Mol BWJ
Hum Reprod; 2018 Oct; 33(10):1907-1914. PubMed ID: 30239784
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
14. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
15. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
16. Complaint-Directed Mini-Interventions for Depressive Symptoms: A Health Economic Evaluation of Unguided Web-Based Self-Help Interventions Based on a Randomized Controlled Trial.
Wijnen BF; Lokman S; Leone S; Evers SM; Smit F
J Med Internet Res; 2018 Oct; 20(10):e10455. PubMed ID: 30274958
[TBL] [Abstract][Full Text] [Related]
17. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
[TBL] [Abstract][Full Text] [Related]
18. The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
Chen X; Hong Y; Zheng P; You X; Feng J; Huang Z; Wang Y
Cancer; 2020 Jan; 126(2):311-321. PubMed ID: 31714584
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
